$NURO
NeuroMetrix, Inc. Stock $nuro

$nuro Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000162828020010566 Filed on July 23, 2020

Income Statement

Concept	2020 Q2	2019 Q2
Revenue	$1.360M	$2.355M
YoY Change	-42.24%	-37.23%
Cost Of Revenue	$495.1K	$3.144M
YoY Change	-84.25%	61.19%
Gross Profit	$864.9K	-$789.1K
YoY Change	-209.6%	-143.81%
Gross Profit Margin	63.6%	-33.51%
Selling, General & Admin	$1.058M	$2.939M
YoY Change	-64.01%	-12.84%
% of Gross Profit	122.28%
Research & Development	$660.3K	$1.035M
YoY Change	-36.2%	-35.99%
% of Gross Profit	76.34%
Depreciation & Amortization	$30.00K	$80.00K
YoY Change	-62.5%	0.0%
% of Gross Profit	3.47%
Operating Expenses	$1.718M	$3.973M
YoY Change	-56.77%	-20.35%
Operating Profit	-$853.0K	-$4.763M
YoY Change	-82.09%	49.43%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$1.051K	$1.400M
YoY Change	-99.92%	13903.38%
Pretax Income	-$850.0K	-$3.360M
YoY Change	-74.7%	-689.47%
Income Tax
% Of Pretax Income
Net Earnings	-$851.9K	-$3.362M
YoY Change	-74.66%	-685.82%
Net Earnings / Revenue	-62.64%	-142.79%
Basic Earnings Per Share	-$0.28	-$0.37
Diluted Earnings Per Share	-$0.28	-$0.37
COMMON SHARES
Basic Shares Outstanding	3.015M shares	904.8K shares
Diluted Shares Outstanding	3.015M shares	904.8K shares

Balance Sheet

Concept	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.430M	$4.960M
YoY Change	9.48%	-30.24%
Cash & Equivalents	$5.435M	$4.958M
Short-Term Investments
Other Short-Term Assets	$190.0K	$1.100M
YoY Change	-82.73%	59.42%
Inventory	$1.192M	$2.063M
Prepaid Expenses
Receivables	$407.7K	$726.7K
Other Receivables	$180.0K	$0.00
Total Short-Term Assets	$7.404M	$8.849M
YoY Change	-16.34%	-21.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$238.4K	$289.5K
YoY Change	-17.66%	-32.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$30.00K	$30.00K
YoY Change	0.0%	-25.0%
Total Long-Term Assets	$1.202M	$1.965M
YoY Change	-38.84%	319.15%
TOTAL ASSETS
Total Short-Term Assets	$7.404M	$8.849M
Total Long-Term Assets	$1.202M	$1.965M
Total Assets	$8.606M	$10.81M
YoY Change	-20.42%	-8.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$190.8K	$1.017M
YoY Change	-81.24%	27.17%
Accrued Expenses	$1.036M	$3.081M
YoY Change	-66.38%	56.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.419M	$4.840M
YoY Change	-50.02%	18.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$700.0K	$1.120M
YoY Change	-37.5%
Total Long-Term Liabilities	$700.0K	$1.120M
YoY Change	-37.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.419M	$4.840M
Total Long-Term Liabilities	$700.0K	$1.120M
Total Liabilities	$3.117M	$5.957M
YoY Change	-47.67%	45.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$196.3M	-$192.3M
YoY Change	2.08%	1.58%
Common Stock	$378.00	$978.00
YoY Change	-61.35%	32.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.489M	$4.858M
YoY Change
Total Liabilities & Shareholders Equity	$8.606M	$10.81M
YoY Change	-20.42%	-8.42%

Cashflow Statement

Concept	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$851.9K	-$3.362M
YoY Change	-74.66%	-685.82%
Depreciation, Depletion And Amortization	$30.00K	$80.00K
YoY Change	-62.5%	0.0%
Cash From Operating Activities	-$1.070M	-$2.240M
YoY Change	-52.23%	-300.0%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$10.00K
YoY Change	0.0%	-90.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$10.00K	-$10.00K
YoY Change	0.0%	-90.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.700M	10.00K
YoY Change	36900.0%
NET CHANGE
Cash From Operating Activities	-1.070M	-2.240M
Cash From Investing Activities	-10.00K	-10.00K
Cash From Financing Activities	3.700M	10.00K
Net Change In Cash	2.620M	-2.240M
YoY Change	-216.96%	-319.61%
FREE CASH FLOW
Cash From Operating Activities	-$1.070M	-$2.240M
Capital Expenditures	-$10.00K	-$10.00K
Free Cash Flow	-$1.060M	-$2.230M
YoY Change	-52.47%	-282.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Gross Profit GrossProfit	2416739	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-287260	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	City Area Code CityAreaCode	781
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Type DocumentType	10-Q
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4B Gill Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Woburn
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01801
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2019Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	62322	USD
CY2020Q2	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	111997	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001289850
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3784657	shares
	nuro	Increase Decrease In Collaboration Receivable IncreaseDecreaseInCollaborationReceivable	-7678	USD
	nuro	Increase Decreasein Accrued Product Returns IncreaseDecreaseinAccruedProductReturns	-360051	USD
	nuro	Increase Decreasein Accrued Product Returns IncreaseDecreaseinAccruedProductReturns	-91000	USD
	nuro	Increase Decreasein Deferred Collaboration Income IncreaseDecreaseinDeferredCollaborationIncome	-1956522	USD
	nuro	Increase Decreasein Deferred Collaboration Income IncreaseDecreaseinDeferredCollaborationIncome	0	USD
CY2020Q2	nuro	Operating Lease Discount OperatingLeaseDiscount	378952	USD
CY2020Q2	nuro	Restricted Cash Collateral Letters Of Credit RestrictedCashCollateralLettersOfCredit	226731	USD
	nuro	Stock Issuance Settle Incentive Compensation Obligation StockIssuanceSettleIncentiveCompensationObligation	0	USD
	nuro	Stock Issuance Settle Incentive Compensation Obligation StockIssuanceSettleIncentiveCompensationObligation	43751	USD
CY2019Q4	nuro	Technology Fees TechnologyFees	450000	USD
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity File Number EntityFileNumber	001-33351
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	NeuroMetrix, Inc.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3308180
	dei	Local Phone Number LocalPhoneNumber	890-9989
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Trading Symbol TradingSymbol	NURO
CY2019Q4	nuro	Accrued Sales Return Provisions AccruedSalesReturnProvisions	689000	USD
CY2020Q2	nuro	Accrued Sales Return Provisions AccruedSalesReturnProvisions	598000	USD
CY2019Q2	nuro	Collaboration Income CollaborationIncome	1381818	USD
	nuro	Collaboration Income CollaborationIncome	7116667	USD
CY2020Q2	nuro	Collaboration Income CollaborationIncome	0	USD
	nuro	Collaboration Income CollaborationIncome	0	USD
CY2019Q4	nuro	Collaborator Payments Receivable CollaboratorPaymentsReceivable	189008	USD
CY2020Q2	nuro	Collaborator Payments Receivable CollaboratorPaymentsReceivable	181330	USD
	nuro	Compensation Obligation Settlement CompensationObligationSettlement	0	USD
	nuro	Compensation Obligation Settlement CompensationObligationSettlement	43751	USD
CY2019	nuro	Facility Relocation Costs FacilityRelocationCosts	100000	USD
	nuro	Idle Facility Impairment Charge IdleFacilityImpairmentCharge	604000	USD
	nuro	Idle Facility Impairment Charge IdleFacilityImpairmentCharge	0	USD
CY2020Q2	nuro	Idle Facility Impairment Charge IdleFacilityImpairmentCharge	117000	USD
	nuro	Idle Facility Impairment Charge IdleFacilityImpairmentCharge	204000	USD
	nuro	Increase Decrease In Collaboration Receivable IncreaseDecreaseInCollaborationReceivable	0	USD
CY2020Q2	nuro	Technology Fees TechnologyFees	450000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	725658	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	190835	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	298967	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	407661	USD
CY2019Q4	us-gaap	Accrued Advertising Current And Noncurrent AccruedAdvertisingCurrentAndNoncurrent	68000	USD
CY2020Q2	us-gaap	Accrued Advertising Current And Noncurrent AccruedAdvertisingCurrentAndNoncurrent	26000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1443574	USD
	us-gaap	Depreciation Depreciation	45589	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1035923	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	454000	USD
CY2020Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	293000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	197319698	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	201787157	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	144047	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44093	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19933	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	128862	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	70000	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	70000	USD
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	585758	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	651246	shares
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	190830	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	198522	shares
CY2019Q4	us-gaap	Assets Assets	6893686	USD
CY2020Q2	us-gaap	Assets Assets	8605528	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	5430814	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	7403682	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3126206	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5434983	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6780429	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4958058	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3126206	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5434983	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1822371	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2308777	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1400674	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3784657	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1400674	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3784657	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	140	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	378	USD
CY2019Q2	us-gaap	Cost Of Revenue CostOfRevenue	3143787	USD
	us-gaap	Cost Of Revenue CostOfRevenue	5468018	USD
CY2020Q2	us-gaap	Cost Of Revenue CostOfRevenue	495086	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1115276	USD
	us-gaap	Depreciation Depreciation	107494	USD
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.72
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.56
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2020Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	270740	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P6M
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1564555	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3184045	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	678497	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-534823	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1930243	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	-789104	USD
	us-gaap	Gross Profit GrossProfit	9600	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	864893	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-356287	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	108694	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	416745	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-599201	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1207451	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	165785	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	247347	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2019Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	166025	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	332049	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	653164	USD
CY2019Q4	us-gaap	Liabilities Liabilities	4363452	USD
CY2020Q2	us-gaap	Liabilities Liabilities	3116912	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6893686	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8605528	USD
CY2020Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	166905	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	333809	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1671106	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	117431	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	321594	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	165785	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28284	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	239749	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-465630	USD
CY2019Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2020Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	443505	USD
CY2020Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	416535	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	1163714	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	1191998	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	720209	USD
CY2020Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	775463	USD
	us-gaap	Inventory Write Down InventoryWriteDown	2595884	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3446778	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2418784	USD
CY2020Q1	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2020-04-30
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7497	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4151037	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7587	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10500	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1822281	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1831760	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	2050507	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-3362191	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1311684	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-657371	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-851944	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1509315	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3362191	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1311684	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-851944	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1509315	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1400338	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	35333	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	333952	USD
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	86226	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7152000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1051	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1549	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	3973425	USD
	us-gaap	Operating Expenses OperatingExpenses	8473284	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	1717888	USD
	us-gaap	Operating Expenses OperatingExpenses	3927603	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4762529	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8463684	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-852995	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1510864	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	588546	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	594026	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	916674	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	698128	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1159774	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	934258	USD
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.15
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2019Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	18520	USD
CY2020Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1051	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1549	USD
CY2020Q1	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	4000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7587	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10500	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	652919	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	187710	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	29650	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	29229	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	773200	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7497	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4151037	USD
CY2019Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	75300	USD
CY2020Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	68700	USD
	us-gaap	Profit Loss ProfitLoss	-1311684	USD
	us-gaap	Profit Loss ProfitLoss	-1509315	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	273448	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	238359	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	773200	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1034921	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1890002	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	660278	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1193898	USD
CY2019	us-gaap	Restructuring Charges RestructuringCharges	2300000	USD
CY2020Q2	us-gaap	Restructuring Reserve RestructuringReserve	400000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-194789605	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-196300000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-196298920	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2354683	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5477618	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1359979	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3532015	USD
CY2019Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1373949	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3399237	USD
CY2020Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	379113	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	803462	USD
CY2019	us-gaap	Severance Costs1 SeveranceCosts1	224773	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	64026	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	272909	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7497	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7606	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	453457	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3689974	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	43751	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	6097811	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	8192411	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	4857650	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	2530234	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	2514118	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	5488616	USD
CY2019Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
	us-gaap	Substantial Doubt About Going Concern Within One Year SubstantialDoubtAboutGoingConcernWithinOneYear	true
CY2019Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	904824	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	839625	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3014523	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2235874	shares
CY2019Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	904824	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	839625	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3014523	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2235874	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-20-010566-index-headers.html	Edgar Link	pending
0001628280-20-010566-index.html	Edgar Link	pending
0001628280-20-010566.txt	Edgar Link	pending
0001628280-20-010566-xbrl.zip	Edgar Link	pending
a10q6302020document.htm	Edgar Link	pending
a10q6302020ex311.htm	Edgar Link	pending
a10q6302020ex312.htm	Edgar Link	pending
a10q6302020ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nuro-20200630.xml	Edgar Link	completed
nuro-20200630.xsd	Edgar Link	pending
nuro-20200630_cal.xml	Edgar Link	unprocessable
nuro-20200630_def.xml	Edgar Link	unprocessable
nuro-20200630_lab.xml	Edgar Link	unprocessable
nuro-20200630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NURO
NeuroMetrix, Inc. Stock $nuro

2020 Q2 Form 10-Q Financial Statement

#000162828020010566 Filed on July 23, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NURO NeuroMetrix, Inc. Stock $nuro

2020 Q2 Form 10-Q Financial Statement

#000162828020010566 Filed on July 23, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NURO
NeuroMetrix, Inc. Stock $nuro